Ovarian cancer trials in Greece
11 trials · From ClinicalTrials.gov, checked 10 Nov 2026. Ask the study team whether a trial fits you.
Phase 3RecruitingTrial-stage medicine
Torvutatug Samrotecan Plus Bevacizumab as First-line Maintenance in Non-Homologous Recombination Deficiency (Non-HRD) Positive Advanced Epithelial Ovarian Cancer
- Where
- Athens, Pátrai, Rio, Thessaloniki
- Age
- 18 years and over
- People
- 950 worldwide
- Run by
- AstraZeneca
See details and how to joinNCT07851025EU 2026-526895-22-00Registry updated 2026-11-06
Phase 3RecruitingTrial-stage medicine
A Three-Part Phase 3 Study of Sofetabart Mipitecan in Participants With Platinum-Resistant (Part A) and Platinum-Sensitive (Parts B and C) Ovarian Cancer
- Where
- Athens, Kalamata, Nea Kifissia
- Age
- 18 years and over
- People
- 1,630 worldwide
- Run by
- Eli Lilly and Company
See details and how to joinNCT07213804EU 2025-522255-25-00Registry updated 2026-11-04
Phase 3RecruitingTrial-stage medicine
Study to Assess the Efficacy and Safety of Rina-S With or Without Bevacizumab Compared to Investigator's Choice of Platinum-based Chemotherapy With or Without Bevacizumab as Second-line Treatment in Participants With Recurrent Platinum-sensitive Ovarian Cancer
- Where
- Athens, Chaïdári, Filothei, Maroussi, Patras
- Age
- 18 years and over
- People
- 688 worldwide
- Run by
- Genmab
See details and how to joinNCT07564141EU 2025-524202-15-00Registry updated 2026-11-04
Phase 3RecruitingTrial-stage medicine
Study of Trastuzumab Deruxtecan With Bevacizumab Versus Bevacizumab Monotherapy for First-line Maintenance in HER2-Expressing Ovarian Cancer (DESTINY-Ovarian01)
- Where
- Athens, Chaïdári, Pireas, Thessaloniki
- Age
- 18 years and over
- People
- 582 worldwide
- Run by
- Daiichi Sankyo
See details and how to joinNCT06819007EU 2024-516982-35-00Registry updated 2026-10-28
Phase 2/3RecruitingTrial-stage medicine
A Study of Raludotatug Deruxtecan (R-DXd) in Subjects With Platinum-resistant, High-grade Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
- Where
- Athens, Filothei, Maroussi, Thessaloniki
- Age
- 18 years and over
- People
- 860 worldwide
- Run by
- Daiichi Sankyo
See details and how to joinNCT06161025EU 2023-507914-28-00Registry updated 2026-10-26
No phaseRecruitingResearch participation
Folate Receptor Alpha (FRα) Expression and Heterogeneity in Epithelial Ovarian Cancer
- Where
- Athens
- Age
- 18 years and over
- People
- 200
- Run by
- Hellenic Cooperative Oncology Group
See details and how to joinNCT07889843Registry updated 2026-10-22
Phase 3RecruitingTrial-stage medicine
A Study to Evaluate the Efficacy and Safety of Sacituzumab Tirumotecan (MK-2870) Maintenance Treatment Versus Standard of Care in Participants With Platinum-sensitive Recurrent Ovarian Cancer (MK-2870-022/TroFuse-022/ENGOT-ov84/GOG-3103)
- Where
- Athens, Chaïdári
- Age
- 18 years and over
- People
- 770 worldwide
- Run by
- Merck Sharp & Dohme LLC
See details and how to joinNCT06824467EU 2023-508015-23-00Registry updated 2026-10-13
Phase 3RecruitingTrial-stage medicine
A Clinical Trial of Sac-TMT in People With Non-HRD Positive Advanced Ovarian Cancer (MK-2870-021)
- Where
- Athens, Thessaloniki
- Age
- 18 years and over
- People
- 900 worldwide
- Run by
- Merck Sharp & Dohme LLC
See details and how to joinNCT07318558EU 2023-508047-40-00Registry updated 2026-10-13
No phaseRecruitingResearch participation
Innovative Ovarian Cancer Biomarker Assays
- Where
- Athens
- Age
- 35 years and over
- People
- 2,080 worldwide
- Run by
- National and Kapodistrian University of Athens
See details and how to joinNCT07693894Registry updated 2026-10-01
No phaseRecruitingResearch participation
CanRisk-Based Ovarian Cancer Risk Assessment Versus Standard Practice (DISARM CSA)
- Where
- Athens
- Age
- 18 years to 75 years
- People
- 2,130 worldwide
- Run by
- Instituto Portugues Oncologia de Lisboa Francisco Gentil
See details and how to joinNCT07809659Registry updated 2026-09-29
Phase 3RecruitingTrial-stage medicine
AZD5335 vs. Mirvetuximab Soravtansine in FRα-high and AZD5335 vs. Chemotherapy in FRα-low Platinum-resistant Ovarian Cancer
- Where
- Athens, Chaïdári, Kalamata, Kifissia, Marousi, Patras, Thessaloniki
- Age
- 18 years and over
- People
- 1,100 worldwide
- Run by
- AstraZeneca
See details and how to joinNCT07218809EU 2025-520466-22-00Registry updated 2026-07-21
All Ovarian cancer trials and the map
This page is not medical advice. Talk to your doctor before contacting a trial.